- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Disruptive Pharma AB: Disruptive Pharma divests GTX platform and retains rights to future royalty and milestone revenues | 139 | GlobeNewswire (Europe) | Disruptive Pharma AB (publ) ("Disruptive Pharma" or the "Company") today announced that it has entered into an agreement to sell the GTX platform to a wholly owned subsidiary of Aurelia Invest AB ("Aurelia").... ► Artikel lesen | |
| 20.08. | Change of issuer name, issuer code/symbol for Guard Therapeutics International AB | 251 | GlobeNewswire | As from August 21, 2026, Guard Therapeutics International AB will change issuer name/issuer code/symbol.
Company name is Disruptive Pharma AB (publ).
Old issuer name: Guard Therapeutics International... ► Artikel lesen | |
| 18.08. | Guard Therapeutics International AB: Disruptive Pharma to ring the opening bell at Nasdaq Stockholm | 427 | GlobeNewswire (Europe) | Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), ("Disruptive Pharma" or the "Company") will ring the opening bell at Nasdaq Stockholm on 21 August 2026. On the same... ► Artikel lesen | |
| 27.07. | The observation status for Guard Therapeutics International AB (publ) is removed | 299 | GlobeNewswire | On December 11, 2025, the shares in Guard Therapeutics International AB (publ) (the "Company") were given observation status with reference to substantial uncertainty regarding the issuer or the... ► Artikel lesen | |
| 27.07. | Guard Therapeutics International Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue | 514 | GlobeNewswire (Europe) | 27 July 2026 - Guard Therapeutics International AB (publ) (to be renamed Disruptive Pharma AB (publ)) ("Guard Therapeutics" or the "Company") today announces that the reverse takeover (RTO) of Disruptive... ► Artikel lesen | |
| 16.07. | Guard Therapeutics International Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description | 232 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today received conditional approval from Nasdaq Stockholm ("Nasdaq") for the continued listing of the Company's... ► Artikel lesen | |
| 11.06. | The observation status for Guard Therapeutics International AB (publ) is updated | 238 | GlobeNewswire | On December 11, 2025, the shares in Guard Therapeutics International AB (publ) (the "Company") were given observation status with reference to information that the Company's board of directors had... ► Artikel lesen | |
| DISRUPTIVE PHARMA Aktie jetzt für 0€ handeln | |||||
| 10.06. | Guard Therapeutics International has entered into a conditional agreement for a reverse takeover with Disruptive Pharma | 338 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today entered into a conditional agreement with shareholders who together hold approximately 91.3 percent of all... ► Artikel lesen | |
| 10.04. | The observation status for Guard Therapeutics International AB (publ) is updated | 310 | GlobeNewswire | On December 11, 2025, the shares in Guard Therapeutics International AB (publ) (the "Company") were given observation status with reference to information that the Company's board of directors had... ► Artikel lesen | |
| 09.04. | Guard Therapeutics International provides information regarding observation status on Nasdaq First North Growth Market | 273 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") today announces that Nasdaq has informed the Company that it currently does not fulfil the ongoing listing requirement... ► Artikel lesen | |
| 31.03. | Guard Therapeutics International provides update on strategic review | 362 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") hereby provides an update regarding the strategic review that was announced in December 2025.
The Company has now completed... ► Artikel lesen | |
| 05.02. | Guard Therapeutics International Announces Changes to the Company's Management Team | 457 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announces changes to the company's management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic review... ► Artikel lesen | |
| 05.02. | Guard Therapeutics International Provides Status Update Regarding Ongoing Strategic Review | 433 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") hereby provides a status update regarding the strategic review that the Company announced through a press release on... ► Artikel lesen | |
| 15.01. | Guard Therapeutics International Partners in EU Consortium For Alport Syndrome | 666 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research... ► Artikel lesen | |
| 11.12.25 | Guard Therapeutics International AB (publ) receives observation status | 335 | GlobeNewswire | On December 4, 2025, Guard Therapeutics International AB (publ) (the "Company") issued a press release with information that the Board of Directors of the Company had resolved to commence an exploratory... ► Artikel lesen | |
| 04.12.25 | Guard Therapeutics International Explores Strategic Alternatives | 375 | GlobeNewswire (Europe) | Guard Therapeutics (publ) ("Guard" or the "Company") today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying... ► Artikel lesen | |
| 04.12.25 | Guard Therapeutics International Provides Assessment of Full POINTER Study Results | 365 | GlobeNewswire (Europe) | Guard Therapeutics (public) ("Guard" or "the Company") today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery.... ► Artikel lesen | |
| 26.10.25 | Guard Therapeutics International Announces Top-Line Results from Phase 2b POINTER Study | 827 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients... ► Artikel lesen | |
| 05.10.25 | Guard Therapeutics International Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study | 419 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 57,06 | -0,21 % | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | ||
| GENMAB | 308,50 | -0,06 % | GENMAB A/S - 6-K, Report of foreign issuer | ||
| ARBUTUS BIOPHARMA | 4,280 | +0,23 % | Arbutus Biopharma Corporation: Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction" Tender Offer | WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,250 | 0,00 % | Nachhaltige Benzinpreise über 2,50 EUR? Nel ASA, Bayer, MustGrow und K+S rücken ins Rampenlicht | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die anhaltende Debatte über steigende Energiekosten und den Wandel hin zu einer umweltfreundlicheren Wirtschaft erreicht zunehmend... ► Artikel lesen | |
| VERICEL | 34,600 | 0,00 % | Vericel Corporation: Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program | Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,603 | +0,17 % | Moleculin Biotech, Inc.: Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 | Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept.... ► Artikel lesen | |
| FAETH THERAPEUTICS | 24,200 | -3,20 % | XFRA 4070: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,065 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.09.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 08.09.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.09.2026.ISIN NameIT0004053440... ► Artikel lesen | |
| REGENXBIO | 6,386 | -1,48 % | Stifel reiterates Regenxbio stock rating on gene therapy data | ||
| ZEVRA THERAPEUTICS | 9,840 | +1,44 % | Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union | Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access... ► Artikel lesen | |
| AKEBIA | 0,783 | 0,00 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases | Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 9,150 | -0,54 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | ~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK- Demand Carried into Third Quarter... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 11,300 | +10,89 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results | Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib's potential in atopic dermatitis... ► Artikel lesen | |
| REVANCE THERAPEUTICS | - | - | Revance hires Janelle Wichmann as chief marketing officer of skincare unit | ||
| CARTESIAN THERAPEUTICS | 6,500 | -2,26 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 Phase 2 TRITON trial of... ► Artikel lesen |
DISRUPTIVE PHARMA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +14,71 % bei einem Aktienkurs von 0,090 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DISRUPTIVE PHARMA AB finden Sie auf Wallstreet Online.